EP1073439A1 - Pharmazeutische zusammenstellungen - Google Patents

Pharmazeutische zusammenstellungen

Info

Publication number
EP1073439A1
EP1073439A1 EP99914373A EP99914373A EP1073439A1 EP 1073439 A1 EP1073439 A1 EP 1073439A1 EP 99914373 A EP99914373 A EP 99914373A EP 99914373 A EP99914373 A EP 99914373A EP 1073439 A1 EP1073439 A1 EP 1073439A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
weight
minoxidil
approximately
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP99914373A
Other languages
English (en)
French (fr)
Other versions
EP1073439B1 (de
EP1073439A4 (de
Inventor
Tony Wai-Chiu So
Peter Paul Deo
Russell John Tait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Research Australia Pty Ltd
Original Assignee
Soltec Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3807366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1073439(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Soltec Research Pty Ltd filed Critical Soltec Research Pty Ltd
Priority to DK06012033.4T priority Critical patent/DK1695708T3/en
Priority to EP06012033.4A priority patent/EP1695708B1/de
Publication of EP1073439A1 publication Critical patent/EP1073439A1/de
Publication of EP1073439A4 publication Critical patent/EP1073439A4/de
Application granted granted Critical
Publication of EP1073439B1 publication Critical patent/EP1073439B1/de
Priority to CY20181100524T priority patent/CY1120513T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a vehicle system for a pharmaceutical composition comprising a piperidinopyrimidine derivative. More particularly minoxidil and to a pharmaceutical composition incorporating the vehicle system.
  • Minoxidil is a pharmaceutically active ingredient having several indications including use as a hair growth stimulant.
  • Minoxidil has poor solubility in water and ethanol and pharmaceutical preparations currently marketed only contain a small percentage of minoxidil. That is, below 5%.
  • the present invention in a first aspect provides a pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.
  • the solubility of the piperidinopyrimidine derivatives may be significantly increased without the necessity of utilising large amounts of propylene glycol or optionally by excluding propylene glycol altogether. Accordingly the total amount of active in the composition may be significantly increased.
  • the pharmaceutically active component is present in amounts of approximately 5 to 25% by weight, preferably approximately 5 to 15% by weight, more preferably approximately 7.5 to 12% by weight.
  • the piperidinopyrimidine derivative is minoxidil.
  • the minoxidil is present in the form of a salt.
  • the salt may include acetate, citrate, succinate, benzoate, hydrochloride, sulphate, phosphate or lactate.
  • an acetate or lactate salt of minoxidil is used.
  • the acetate or lactate salts may exhibit enhanced solubility and improve the ability to incorporate increased amounts of the active component in the composition.
  • the acid is added in an amount sufficient to provide an 3 apparent pH to the composition of approximately 7.0 or less.
  • the apparent pH of the composition is preferably between approximately 5.0 to 7.0, more preferably between 6.0 to 6.5.
  • Any suitable acid may be used to adjust the pH, including mineral acids, such as hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid, or organic acids such as citric acid, acetic acid, succinic acid, or maleic acid, or mixtures thereof.
  • Acetic acid or lactic acid is preferred.
  • the acid is present at a level that provides at least 0.01 Normal acid.
  • the acid is present in an amount equal to, or greater than, the amount of the piperidinopyrimidine derivative in Normal amounts.
  • the lower alcohol is ethanol.
  • the ratio of water to ethanol is preferably from approximately 9:1 to 1 ;9, more preferably approximately 1 :1 to 1 :3, by volume.
  • the co-solvent includes benzyl alcohol.
  • the benzyl alcohol may be present in amounts of approximately 2.5 to 95% by weight, preferably approximately 5 to 40% by weight, based on the total weight of the pharmaceutical composition.
  • the co-solvent may include a polyhydric alcohol, for example a polyol selected from the group consisting of 1 ,3-butylene glycol, propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol.
  • a polyhydric alcohol for example a polyol selected from the group consisting of 1 ,3-butylene glycol, propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol.
  • propylene glycol When propylene glycol is present, it may be present in amounts of approximately 10% by weight or less, preferably approximately 5% by weight, or less.
  • compositions comprising 5% of minoxidil or greater, it is preferred to include benzyl alcohol in the composition.
  • the benzyl alcohol may be present in amounts of up to 85% by weight, based on the total weight of the pharmaceutical composition.
  • the co-solvent system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by 4 weight, based on the total weight of the co-solvent system.
  • the water is present in an amount no greater than 60% by weight.
  • the pharmaceutical composition includes approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt; approximately 88 to 95% by weight of a solvent composition including approximately 10 to 70% by weight of ethanol, approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glycol.
  • compositions may be any suitable topical pharmaceutical preparation and may include solutions, lotions, ointments, mousses, foams, sprays, aerosols, shampoos and/or conditioners, gels, creams, pastes, and other preparations known in the art.
  • the composition may also include other ingredients such as preservatives, buffers, stabilisers, propellants and the like.
  • the pharmaceutical composition is a mousse composition.
  • the mousse composition may include a suitable propellant, for example hydrocarbons or chlorofluorocarbons.
  • the pharmaceutical composition may be a gel composition.
  • the gel composition may include a suitable gelling agent, e.g. a cellulose derivative. A hydroxy propyl cellulose, for example that sold under the trade designation Klucel M, has been found to be suitable.
  • the aerosol formulation may be a homogeneous, aqueous-alcoholic emulsion system.
  • the aerosol formulation upon actuation produces a stabilized, homogeneous, expandable foam which breaks easily with shear.
  • a composition of this type is sometimes referred to as a
  • the pharmaceutical composition according to 5 the present invention may further include an effective amount of a skin penetrating agent.
  • Suitable skin penetrating agents include alcohols such as dodecanol and oleyl alcohol; amines, such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine; carboxylic acids, such as oleic acid, linoleic acid and linolenic acid; esters, such as dibutyl sebacate, dibutyl phthalate, butyl benzoate and ethyl caprate; and others, such as Azone, N methyl pyrollidone, bile salts and urea.
  • alcohols such as dodecanol and oleyl alcohol
  • amines such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine
  • carboxylic acids such as oleic acid, linoleic
  • compositions herein may be actuated using propellants known per se in the pharmaceutical or cosmetic fields.
  • propellants include hydrocarbons such as propane, isobutane or dimethyl ether and chlorofluorocarbons such as P-12, P114, and a 40:60 mixture thereof.
  • general purpose components ordinarily used in hair treatment compositions can be formulated, within a range which does not impair the effect of the present invention, including vitamins such as vitamin B.sub.6, vitamin E and derivatives thereof, and biotin; hair generating agents or hair generating aids such as panthothenic acid and derivatives thereof, glycylrrhetic acid and derivatives thereof, nicotinic acid esters such as benzyl nicotinate, cyclosporins, carpronium chloride, cepharanthine, oxendolone, diazoxide, minoxidil, and ethynylesteradiol; antibacterial agents such as hinokitiol, hexachlorophen, phenol, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, and bithionol; refrigerants such as
  • a method for the treatment of hair loss and related indications in humans which method 6 includes providing a pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.
  • a pharmaceutical composition for topical administration including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable
  • the hair loss may be related to any of the forms of alopecia including male pattern alopecia.
  • Related indications may include weakening of hair strength, loss of hair colour and the like.
  • the pharmaceutically active component includes a minoxidil or a minoxidil salt, more preferably a minoxidil acetate, succinate or citrate salt.
  • the pharmaceutical composition includes approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt; approximately 88 to 95% by weight of a solvent composition including approximately 10 to 70% by weight of ethanol, approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glycol.
  • the apparent pH of each formulation was measured once prepared. The measured taken as the apparent pH due to the high proportion of organic modifiers in the formulations. Typically, 0.5% (w/w) glacial acetic acid (0.1 M) would be used in the formulation, which would equate to a pH of 1.0 in an aqueous system when no other components are contributing to the pH of the solution.
  • the apparent pH of the final formulated solution was measured at 6.24.
  • aqueous gel was prepared by adding 0.75% (w/w) Klucel M (hydroxypropyl cellulose) to Example 4. The viscosity of the gel was measured at 13
  • the solubility determination involved preparation of saturated solutions of minoxidil in the media of interest. These solutions were then filtered (0.45 ⁇ m) and analysed against a standard curve by means of direct UV spectroscopy.
  • the aqueous solubility of minoxidil was found to be 2.2 mg/mL.
  • the solubility of minoxidil was determined in each of the co-solvents, benzyl alcohol, glycerol, propylene glycol and ethanol. Additionally, the solubility of minoxidil was determined in 10% (w/w) solutions of each of the co-solvents, ethanol, propylene glycol and glycerol in water. A 4% (w/w) solution of benzyl alcohol was used since this was found to be the limit of the solubility of benzyl alcohol in water. The following table summarises the results of these studies. 14
  • Minoxidil base was used for these studies with the appropriate salt (acetate or HCI) formed in situ. As discussed above the use of low pH acetate buffers significantly increased the solubility of minoxidil.
  • the acid form of minoxidil has been shown to be much more soluble in an aqueous environment.
  • the use of co-solvents has been shown to enhance the solubility of the minoxidil free base.
  • the co-solvents may also enhance the solubility of the acid form.
  • the use of an appropriate salt enhances the solubility of the acid form of minoxidil. Therefore, a combination of these three factors may be used to optimise the solubility of minoxidil in a topical solution based formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EP99914373A 1998-04-22 1999-04-20 Pharmazeutische zusammenstellungen Expired - Lifetime EP1073439B1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK06012033.4T DK1695708T3 (en) 1998-04-22 1999-04-20 Highly concentrated minoxidil composition
EP06012033.4A EP1695708B1 (de) 1998-04-22 1999-04-20 Hochkonzentrierte Minoxidil Zusammenstellungen
CY20181100524T CY1120513T1 (el) 1998-04-22 2018-05-18 Υψηλης συμπυκνωσης συνθεση μινοξιδιλης

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP310798 1998-04-22
AUPP3107A AUPP310798A0 (en) 1998-04-22 1998-04-22 Vehicle system for a composition comprising a piperidinopyrimidine derivative
PCT/AU1999/000294 WO1999053923A1 (en) 1998-04-22 1999-04-20 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06012033.4A Division EP1695708B1 (de) 1998-04-22 1999-04-20 Hochkonzentrierte Minoxidil Zusammenstellungen

Publications (3)

Publication Number Publication Date
EP1073439A1 true EP1073439A1 (de) 2001-02-07
EP1073439A4 EP1073439A4 (de) 2003-07-02
EP1073439B1 EP1073439B1 (de) 2006-06-28

Family

ID=3807366

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06012033.4A Expired - Lifetime EP1695708B1 (de) 1998-04-22 1999-04-20 Hochkonzentrierte Minoxidil Zusammenstellungen
EP99914373A Expired - Lifetime EP1073439B1 (de) 1998-04-22 1999-04-20 Pharmazeutische zusammenstellungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06012033.4A Expired - Lifetime EP1695708B1 (de) 1998-04-22 1999-04-20 Hochkonzentrierte Minoxidil Zusammenstellungen

Country Status (13)

Country Link
US (2) US6946120B2 (de)
EP (2) EP1695708B1 (de)
JP (3) JP3710380B2 (de)
AT (1) ATE331517T1 (de)
AU (1) AUPP310798A0 (de)
BR (1) BR9909796B1 (de)
CA (1) CA2328950C (de)
CY (1) CY1120513T1 (de)
DE (1) DE69932158T2 (de)
DK (2) DK1073439T3 (de)
ES (2) ES2268856T3 (de)
PT (2) PT1695708T (de)
WO (1) WO1999053923A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
JPH11349451A (ja) * 1998-06-08 1999-12-21 Taisho Pharmaceut Co Ltd 育毛剤
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
JP4892786B2 (ja) * 2000-04-07 2012-03-07 大正製薬株式会社 持続性育毛製剤
DE60114168T2 (de) * 2000-04-07 2006-07-13 Taisho Pharmaceutical Co., Ltd. Haarwachstumstimulierende mittel mit verlängerter wirkung
ES2245980T3 (es) * 2000-04-07 2006-02-01 Taisho Pharmaceutical Co., Ltd Composiciones estimulantes del crecimiento capilar.
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
AUPR048600A0 (en) * 2000-10-02 2000-10-26 Soltec Research Pty Ltd Pharmaceutical vehicle
ATE368463T1 (de) * 2001-05-15 2007-08-15 Taisho Pharmaceutical Co Ltd Minoxidil-enthaltende flüssige zusammensetzung
SE0104421D0 (sv) 2001-12-21 2001-12-21 Ponsus Pharma Ab New composition
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
BR0314916A (pt) 2002-10-25 2005-08-16 Foamix Ltd Espuma farmacêutica e cosmética
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
RS20050557A (en) 2003-01-24 2007-09-21 Connetics Australia Pty Ltd., Clindamycin phosphate foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
AU2004275900B2 (en) * 2003-09-29 2010-04-29 Deb Ip Limited High alcohol content gel-like and foaming compositions
GB0323908D0 (en) * 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
AU2003299882A1 (en) * 2003-12-22 2005-08-03 Regrowth, Llc Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20050163811A1 (en) * 2004-01-23 2005-07-28 Richard Lee Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
US8263098B2 (en) 2005-03-07 2012-09-11 Deb Worldwide Healthcare Inc. High alcohol content foaming compositions with silicone-based surfactants
BRPI0612448A2 (pt) 2005-05-09 2010-11-23 Foamix Ltd composição espumosa de sacarìdeo
PL1917072T3 (pl) * 2005-06-01 2014-01-31 Glaxosmithkline Ip Dev Ltd Formulacja witaminowa
US8147815B2 (en) * 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
WO2008007224A2 (en) 2006-03-31 2008-01-17 Stiefel Research Australia Pty Ltd Foamable suspension gel
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
KR100893469B1 (ko) * 2006-12-22 2009-04-17 씨제이제일제당 (주) 피부 투과성이 우수한 미녹시딜 함유 발모용 외용액제조성물
US8580860B2 (en) * 2007-02-23 2013-11-12 Gojo Industries, Inc. Foamable alcoholic composition
US8021649B2 (en) * 2007-02-22 2011-09-20 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
EP2242476A2 (de) 2008-01-14 2010-10-27 Foamix Ltd. Aufschäumbare pharmazeutische poloxamer-zusammensetzungen mit wirkstoffen und/oder therapeutischen zellen und verwendungen
JP5420946B2 (ja) * 2009-03-23 2014-02-19 富士フイルム株式会社 胆汁酸を含むミノキシジル水性組成物
JP2010222317A (ja) * 2009-03-25 2010-10-07 Shiseido Co Ltd 水中油型乳化化粧料
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
DK2473161T3 (en) 2009-08-31 2017-09-11 Dr Reddys Laboratories Ltd TOPICAL FORMULATIONS INCLUDING A STEROID
CA2776471C (en) 2009-10-02 2019-02-12 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US20110189114A1 (en) * 2010-01-29 2011-08-04 Nyangenya Maniga minoxidil composition and non-aerosol, non-spray foam method of delivery therefor
US9271917B2 (en) 2010-01-29 2016-03-01 Nyangenya Maniga Method and apparatus for delivery of a measured dosage of a non-aerosol, non-spray foam composition of minoxidil
WO2012040342A2 (en) * 2010-09-21 2012-03-29 Conrex Pharmaceutical Corporation Restoration of hair
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
EP2906199B1 (de) 2012-10-11 2018-01-03 Anaplasi Pharmaceuticals LLC Verfahren und zusammensetzungen zur behandlung von schuppenflechte
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
WO2014122436A1 (en) 2013-02-07 2014-08-14 Cipla House Topical pharmaceutical compositions comprising minoxidil
US8642097B1 (en) 2013-03-19 2014-02-04 Nyangenya Maniga Natural product energy drink and method of use thereof
WO2014184173A1 (en) 2013-05-14 2014-11-20 Montero Gida Sanayi Ve Ticaret A.S. Hair care formulations
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9474699B2 (en) 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
US9468606B2 (en) 2014-03-31 2016-10-18 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of an acidic benefit agent
KR20170012564A (ko) 2014-06-16 2017-02-02 존슨 앤드 존슨 컨수머 인코포레이티드 색조 화장료의 국소 도포를 향상시키기 위한 조성물 및 방법
WO2015195304A1 (en) 2014-06-17 2015-12-23 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for enhancing the topical application of a benefit agent including powder to liquid particles and a second powder
US9675537B2 (en) 2014-06-30 2017-06-13 Johnson & Johnson Consumer Inc. Hair growth composition and method
JP7072346B2 (ja) * 2015-03-27 2022-05-20 大正製薬株式会社 ローション剤
WO2016159916A1 (en) * 2015-03-31 2016-10-06 Ogi̇g Sağlik Ürünleri̇ Ve Hi̇zmetleri̇ Sanayi̇ Ti̇caret Li̇mi̇ted Şi̇rketi̇ A foamy pharmaceutical formulation used in dermatological diseases
WO2016186896A1 (en) * 2015-05-18 2016-11-24 Thrower Angelo Perry Hair regrowth treatment and growth stimulant
US11185672B2 (en) 2015-09-27 2021-11-30 Follica, Inc. Needling device and drug applicator
ES2809704T3 (es) 2015-10-06 2021-03-05 Assos Ilac Kimya Gida Ueruenleri Ueretim Ve Tic A S Composición tópica de minoxidil
US10561593B2 (en) * 2015-12-28 2020-02-18 Johnson & Johnson Consumer Inc. Hair growth composition and method
CN105434352A (zh) * 2015-12-31 2016-03-30 浙江万晟药业有限公司 一种米诺地尔泡沫剂及其制备方法与应用
JP2018048105A (ja) * 2016-01-22 2018-03-29 大正製薬株式会社 外用組成物
JP2018048104A (ja) * 2016-01-22 2018-03-29 大正製薬株式会社 外用組成物
JP6848565B2 (ja) * 2016-03-30 2021-03-24 大正製薬株式会社 エアゾール剤
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
JP7366515B2 (ja) * 2016-09-15 2023-10-23 大正製薬株式会社 外用組成物
US9962444B2 (en) 2016-09-27 2018-05-08 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
JP6990992B2 (ja) 2017-05-25 2022-01-12 フクダ電子株式会社 生体信号記録装置およびその制御方法
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
EP3801734A4 (de) 2018-05-30 2022-03-16 Follica, Inc. Verfahren zur förderung von haarwachstum
JP2019210268A (ja) * 2018-05-30 2019-12-12 ダイヤ製薬株式会社 外用剤及び外用剤の製造方法
EP3750528A1 (de) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Zusammensetzungen zur behandlung von dystrophien und myotonie
EA202290013A1 (ru) 2019-06-28 2022-03-18 Общество С Ограниченной Ответственностью "Регеус" Средство для усиления роста волос
PL3886799T3 (pl) 2019-08-07 2024-03-18 Aneira Pharma, Inc. Kompozycje do leczenia utraty włosów
BR102021003531A2 (pt) 2021-02-24 2022-08-30 Eurofarma Laboratorios S.A. Composição farmacêutica tópica espumável

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0211268A2 (de) * 1985-07-19 1987-02-25 Vincenzo Zappia Topische Präparate mit verzögerter Freigabe
WO1997012602A1 (en) * 1995-10-06 1997-04-10 The Regents Of The University Of Michigan Stimulation of hair follicles

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US515836A (en) * 1894-03-06 Basin-clamp
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
IT1066697B (it) * 1976-11-08 1985-03-12 Manetti & Roberts Italo Brit Attivatore per composizioni cosmetiche e composizioni cosmetiche che lo contengono
US5183817A (en) * 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
WO1983002558A1 (en) * 1981-11-09 1983-08-04 Gail Sansone Bazzano The use of retinoids and minoxidil (2,4,-diamino-6-piperidino-pyrimidine-3-oxide) to increase the rate of growth of human scalp hair and to treat certain types of alopecias
AU565146B2 (en) 1983-10-24 1987-09-03 Connetics Australia Pty Ltd Foamable biocide composition
WO1986000196A1 (en) 1984-06-21 1986-01-16 Soltec Research Pty. Ltd. Aerosol product
JPS61197161A (ja) 1985-02-25 1986-09-01 Amada Co Ltd ドレツシング装置
EP0249397B1 (de) * 1986-06-13 1992-08-12 The Procter & Gamble Company Topische pharmazeutische Zubereitung mit besserer Durchdringungsfähigkeit
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
LU86548A1 (fr) 1986-08-07 1988-03-02 Oreal Composition sous forme de gel pour induire et stimuler la croissance des cheveux et diminuer leur chute a base de derives de piperidino-pyrimidine
EP0316364B1 (de) 1986-08-08 1992-03-18 The Upjohn Company Mittel zur behandlung von alopezien
AU8025787A (en) 1986-09-12 1988-04-07 Upjohn Company, The Foams for delivery of minoxidil
JPS63150211A (ja) 1986-12-15 1988-06-22 Taisho Pharmaceut Co Ltd ミノキシジル配合外用剤
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4882182A (en) 1987-01-08 1989-11-21 Soltec Research Pty. Ltd. Aerosol product
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
JP2810040B2 (ja) * 1987-09-09 1998-10-15 株式会社資生堂 頭皮・頭髪用養毛料
JP2810041B2 (ja) 1987-09-09 1998-10-15 株式会社資生堂 頭皮・頭髪用養毛料
JPH0745387B2 (ja) 1987-09-09 1995-05-17 株式会社資生堂 発毛、養毛促進剤
KR910010018B1 (ko) 1987-10-02 1991-12-10 가부시기가이샤 시세이도 양모제
US4866067A (en) * 1987-12-07 1989-09-12 Ricerche De Schiena s.n.c del Dr. Michele Giuseppe Di Schiena & C. 6-piperidino-2,4-diaminopyrimidine-3-oxide salt of 3-carboxypyridine n-oxide and topical, related compositions
US4888354A (en) 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
WO1989007436A1 (en) 1988-02-18 1989-08-24 The Upjohn Company Minoxidil gel
US5225189A (en) 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
AU619256B2 (en) 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
LU87249A1 (fr) 1988-06-17 1990-02-28 Oreal Composition pour induire et stimuler la croissance des cheveux et/ou freiner leur chute,a base d'un agent tensio-actif amphotere et d'un derive de pyrimidine
US4938953A (en) 1988-08-09 1990-07-03 The Upjohn Company Self-preserving conditioning shampoo formulation
US5104646A (en) 1989-08-07 1992-04-14 The Procter & Gamble Company Vehicle systems for use in cosmetic compositions
CA2085605C (en) 1990-08-10 2003-03-11 Arthur Robert Diani Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors
US5935554A (en) 1990-09-03 1999-08-10 Soltec Research Pty. Ltd. Concentrated aerosol space spray that is not an emulsion
WO1992004419A1 (en) 1990-09-03 1992-03-19 Soltec Research Pty. Ltd. A concentrated aerosol space spray
CA2104858A1 (en) * 1991-03-19 1992-09-20 Steven H. Leitch Hair care compositions having styling/conditioning agent and plasticizer
ZA94170B (en) 1993-01-20 1995-03-15 Soltec Res Pty Ltd Ectoparasiticidal formulation
JPH0748230A (ja) * 1993-07-31 1995-02-21 Hideo Horiuchi 育毛剤の製造法
FR2717683B1 (fr) 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition capillaire à base de minoxidil.
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US5783202A (en) 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
FR2736824B1 (fr) * 1995-07-18 1997-10-10 Fabre Pierre Dermo Cosmetique Composition capillaire a base de minoxidil a faible teneur en solvant gras
JPH0971513A (ja) 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
JP4467085B2 (ja) * 1996-01-05 2010-05-26 大正製薬株式会社 ヒノキチオール含有組成物
JPH09188629A (ja) 1996-01-06 1997-07-22 Pola Chem Ind Inc 抗体産生細胞抑制剤及びそれを含有する組成物
US5788155A (en) 1996-06-28 1998-08-04 S. C. Johnson & Son, Inc. Air freshener dispenser device with dual cartridge capacity
US5838669A (en) 1996-08-28 1998-11-17 At&T Corp. Method of synchronizing satellite switched CDMA communication system
JP3061575B2 (ja) 1996-10-17 2000-07-10 日立建機株式会社 孔掘削装置
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
JPH10158782A (ja) 1996-12-05 1998-06-16 Nkk Corp フォトエッチング時の穿孔性とプレス成形性に優れたシャドウマスク用鋼板及びその製造方法
US6255313B1 (en) 1997-01-23 2001-07-03 Taisho Pharmaceutical Co., Ltd. Sustained release hair growth composition
JPH10265343A (ja) 1997-01-23 1998-10-06 Taisho Pharmaceut Co Ltd 持効性育毛剤
JPH10279437A (ja) * 1997-03-31 1998-10-20 Shiseido Co Ltd 頭髪用化粧料
AUPO688997A0 (en) 1997-05-20 1997-06-12 Soltec Research Pty Ltd Sunscreen composition
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
JPH11302131A (ja) * 1998-04-15 1999-11-02 Shiseido Co Ltd 頭皮頭髪用化粧料
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
JPH11349451A (ja) 1998-06-08 1999-12-21 Taisho Pharmaceut Co Ltd 育毛剤
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AUPQ002999A0 (en) 1999-04-29 1999-05-20 Soltec Research Pty Ltd Non-aqueous shampoo composition
ES2245980T3 (es) 2000-04-07 2006-02-01 Taisho Pharmaceutical Co., Ltd Composiciones estimulantes del crecimiento capilar.
JP4780429B2 (ja) 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
US20030157046A1 (en) 2000-04-07 2003-08-21 Koji Imamura Minoxidil-containing preparations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0211268A2 (de) * 1985-07-19 1987-02-25 Vincenzo Zappia Topische Präparate mit verzögerter Freigabe
WO1997012602A1 (en) * 1995-10-06 1997-04-10 The Regents Of The University Of Michigan Stimulation of hair follicles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9953923A1 *

Also Published As

Publication number Publication date
EP1695708A2 (de) 2006-08-30
EP1695708B1 (de) 2018-02-28
ES2665271T3 (es) 2018-04-25
ES2268856T3 (es) 2007-03-16
CY1120513T1 (el) 2019-07-10
DE69932158T2 (de) 2007-05-10
DK1073439T3 (da) 2006-10-23
JP2004059587A (ja) 2004-02-26
CA2328950C (en) 2008-07-29
US6946120B2 (en) 2005-09-20
CA2328950A1 (en) 1999-10-28
BR9909796A (pt) 2000-12-26
AUPP310798A0 (en) 1998-05-14
ATE331517T1 (de) 2006-07-15
JP2007137899A (ja) 2007-06-07
JP3710380B2 (ja) 2005-10-26
DE69932158D1 (de) 2006-08-10
WO1999053923A1 (en) 1999-10-28
EP1073439B1 (de) 2006-06-28
DK1695708T3 (en) 2018-04-23
US20050037060A1 (en) 2005-02-17
US20020172649A1 (en) 2002-11-21
PT1073439E (pt) 2006-11-30
PT1695708T (pt) 2018-05-18
JP2002512192A (ja) 2002-04-23
EP1073439A4 (de) 2003-07-02
JP4338455B2 (ja) 2009-10-07
BR9909796B1 (pt) 2013-10-29
EP1695708A3 (de) 2012-07-18

Similar Documents

Publication Publication Date Title
CA2328950C (en) Piperidinopyrimidine derivatives for topical application
EP0315648B1 (de) Sebum lösende, nicht wässrige minoxidil-formulierung
WO1988001863A1 (en) Foams for delivery of minoxidil
CA2170016C (en) Improved method for treating hair loss
JP2002524490A (ja) ムースの組成
IE913469A1 (en) Novel composition
JPH08277209A (ja) 育毛剤
JP4940527B2 (ja) 持続性育毛組成物
JP2733980B2 (ja) 養毛組成物
AU757601B2 (en) Pharmaceutical composition
JPH11349451A (ja) 育毛剤
JP4604489B2 (ja) 持続性育毛製剤
CN116600786A (zh) 含有jak抑制剂和月桂醇聚醚-4的局部制剂
JPH0971513A (ja) 育毛剤
JP2600794B2 (ja) 発毛剤
JPH04108722A (ja) 発毛剤
JP4892786B2 (ja) 持続性育毛製剤
JPH04120011A (ja) 発毛剤
JPH04159207A (ja) 発毛剤
NZ223913A (en) Percutaneous absorption promoting agent containing an anionic surfactant and a nitrogen-containing surfactant other than an anionic surfactant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CONNETICS AUSTRALIA PTY LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20030519

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 47/12 B

Ipc: 7A 61P 17/14 B

Ipc: 7A 61K 7/06 B

Ipc: 7A 61K 31/506 B

Ipc: 7A 61K 31/505 A

17Q First examination report despatched

Effective date: 20030918

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/12 20060101ALI20060105BHEP

Ipc: A61P 17/14 20060101ALI20060105BHEP

Ipc: A61K 31/506 20060101ALI20060105BHEP

Ipc: A61K 31/505 20060101AFI20060105BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 7/00 20060101ALI20060110BHEP

Ipc: A61K 47/12 20060101ALI20060110BHEP

Ipc: A61P 17/14 20060101ALI20060110BHEP

Ipc: A61K 31/506 20060101ALI20060110BHEP

Ipc: A61K 31/505 20060101AFI20060110BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20060628

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69932158

Country of ref document: DE

Date of ref document: 20060810

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20060403102

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20060922

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2268856

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070329

REG Reference to a national code

Ref country code: PT

Ref legal event code: PD4A

Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD, AU

Effective date: 20070619

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD.

Free format text: CONNETICS AUSTRALIA PTY LIMITED#8 MACRO COURT#ROWVILLE VICTORIA 3178 (AU) -TRANSFER TO- STIEFEL RESEARCH AUSTRALIA PTY LTD.#8 MACRO COURT#ROWVILLE, VICTORIA 3178 (AU)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD.

Free format text: STIEFEL RESEARCH AUSTRALIA PTY LTD.#8 MACRO COURT#ROWVILLE, VICTORIA 3178 (AU) -TRANSFER TO- STIEFEL RESEARCH AUSTRALIA PTY LTD.#8 MACRO COURT#ROWVILLE, VICTORIA 3178 (AU)

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1034443

Country of ref document: HK

BECN Be: change of holder's name

Owner name: STIEFEL RESEARCH AYSTRALIA PTY LTD

Effective date: 20060628

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD.

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20180329

Year of fee payment: 20

Ref country code: DK

Payment date: 20180322

Year of fee payment: 20

Ref country code: FI

Payment date: 20180323

Year of fee payment: 20

Ref country code: GB

Payment date: 20180328

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20180327

Year of fee payment: 20

Ref country code: PT

Payment date: 20180326

Year of fee payment: 20

Ref country code: FR

Payment date: 20180320

Year of fee payment: 20

Ref country code: IE

Payment date: 20180323

Year of fee payment: 20

Ref country code: GR

Payment date: 20180323

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20180405

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20180504

Year of fee payment: 20

Ref country code: CH

Payment date: 20180425

Year of fee payment: 20

Ref country code: DE

Payment date: 20180409

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20180412

Year of fee payment: 20

Ref country code: AT

Payment date: 20180323

Year of fee payment: 20

Ref country code: BE

Payment date: 20180417

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20180409

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20180321

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69932158

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20190420

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20190419

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20190419

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20190420

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 331517

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20190420

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20190419

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20190421